IDX-184

{{Drugbox
| IUPAC_name = S-[2-{[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl}oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate
| image = IDX-184_structure.png
| width = 260

| tradename =
| legal_US = 研究药物
| legal_status =

| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =

| CAS_number = 1036915-08-8
| CAS_number_Ref =
| PubChem = 135565589
| UNII = 4W44B4S9OC
| ChemSpiderID = 34066446

| C=25 | H=35 | N=6 | O=9 | P=1 | S=1
| molecular_weight = 626.6
| SMILES = C[C@]1(C@@HN)COP(=O)(NCC4=CC=CC=C4)OCCSC(=O)C(C)(C)CO)O)O
| StdInChI=1S/C25H35N6O9PS/c1-24(2,13-32)22(35)42-10-9-38-41(37,28-11-15-7-5-4-6-8-15)39-12-16-18(33)25(3,36)21(40-16)31-14-27-17-19(31)29-23(26)30-20(17)34/h4-8,14,16,18,21,32-33,36H,9-13H2,1-3H3,(H,28,37)(H3,26,29,30,34)/t16-,18-,21-,25-,41?/m1/s1
| StdInChIKey = FGHMGRXAHIXTBM-TWFJNEQDSA-N
}}

IDX-184是一种抗病毒药物，开发用作 RNA聚合酶抑制剂来治疗丙型肝炎。尽管它在早期臨床試驗中显示出一定效果，但并未通过IIb期试验。然而，该药物的研究仍在继续，并对一些新病毒（如茲卡病毒、MERS和SARS-CoV-2等冠状病毒）显示出一定的药物活性。

参考文献